Next Article in Journal
Reversible Cross-Linked Mixed Micelles for pH Triggered Swelling and Redox Triggered Degradation for Enhanced and Controlled Drug Release
Previous Article in Journal
Topical Pioglitazone Nanoformulation for the Treatment of Atopic Dermatitis: Design, Characterization and Efficacy in Hairless Mouse Model
Previous Article in Special Issue
MHC Class I Stability is Modulated by Cell Surface Sialylation in Human Dendritic Cells
Open AccessReview

Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity

1
Departamento de Biología Molecular, Universidad Nacional de Río Cuarto, Río Cuarto 5800, Córdoba, Argentina
2
INBIAS, CONICET-UNRC, Río Cuarto 5800, Córdoba, Argentina
3
Department of Medicine, Surgery and Dentistry ‘Scuola Medica Salernitana’, University of Salerno, 84081 Baronissi, Salerno, Italy
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2020, 12(3), 256; https://doi.org/10.3390/pharmaceutics12030256 (registering DOI)
Received: 28 January 2020 / Revised: 5 March 2020 / Accepted: 10 March 2020 / Published: 12 March 2020
(This article belongs to the Special Issue Dendritic Cell Vaccines)
The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not achieve the clinical benefits that were predicted in a number of promising preclinical studies. The current availability of several immune modulatory and targeting approaches opens the way to many potential therapeutic combinations. In particular, the evidence that the immune-related effects that are elicited by immunogenic cell death (ICD)-inducing therapies are strictly associated with DC engagement and activation strongly support the combination of ICD-inducing and DC-based immunotherapies. In this review, we examine the data in recent studies employing tumor cells, killed through ICD induction, in the formulation of anticancer DC-based vaccines. In addition, we discuss the opportunity to combine pharmacologic or physical therapeutic approaches that can promote ICD in vivo with in situ DC vaccination. View Full-Text
Keywords: immunogenic cell death; dendritic cell-based vaccination; immunotherapy; cancer treatment immunogenic cell death; dendritic cell-based vaccination; immunotherapy; cancer treatment
Show Figures

Graphical abstract

MDPI and ACS Style

Lamberti, M.J.; Nigro, A.; Mentucci, F.M.; Rumie Vittar, N.B.; Casolaro, V.; Dal Col, J. Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity. Pharmaceutics 2020, 12, 256.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop